News

EP PerMed - New Fast Track and Venture Creator Programmes

Published on | 1 year ago

Programmes Health

The European Partnership for Personalised Medicine (EP PerMed) introduces two new opportunities for start-ups, researchers, and early-stage teams working on cutting-edge solutions in personalised medicine. These programmes aim to accelerate the development, validation, and market readiness of transformative innovations that enhance patient care:

  • Fast Track Validation Programme 
    Designed to address a critical bottleneck in personalised medicine development, this programme supports validation studies to elevate projects to higher technological and market readiness levels.
    Join the info webinar on 21 January 2025 here

  • Ventior Creation Programme
    This programme empowers early-stage ventures or teams in personalised medicine by bridging the gap between innovation and commercialisation through mentoring, business model development, and customer discovery.
    Join the info webinar on 28 January 2025 here

Submission deadline is 13 March 2025

Find out more
about both calls and how to apply on the EP PerMed website.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1780 articles available search in articles 

Testimonial

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.